Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial.
Recourt K, van der Aart J, Jacobs G, de Kam M, Drevets W, van Nueten L, Kanhai K, Siebenga P, Zuiker R, Ravenstijn P, Timmers M, van Gerven J, de Boer P. Recourt K, et al. Among authors: ravenstijn p. J Psychopharmacol. 2020 Sep;34(9):1030-1042. doi: 10.1177/0269881120914206. Epub 2020 Apr 4. J Psychopharmacol. 2020. PMID: 32248747 Clinical Trial.
Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants.
Timmers M, Ravenstijn P, Xi L, Triana-Baltzer G, Furey M, Van Hemelryck S, Biewenga J, Ceusters M, Bhattacharya A, van den Boer M, van Nueten L, de Boer P. Timmers M, et al. Among authors: ravenstijn p. J Psychopharmacol. 2018 Dec;32(12):1341-1350. doi: 10.1177/0269881118800067. Epub 2018 Sep 27. J Psychopharmacol. 2018. PMID: 30260294 Clinical Trial.
18F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446.
Koole M, Schmidt ME, Hijzen A, Ravenstijn P, Vandermeulen C, Van Weehaeghe D, Serdons K, Celen S, Bormans G, Ceusters M, Zhang W, Van Nueten L, Kolb H, de Hoon J, Van Laere K. Koole M, et al. Among authors: ravenstijn p. J Nucl Med. 2019 May;60(5):683-690. doi: 10.2967/jnumed.118.216747. Epub 2018 Sep 27. J Nucl Med. 2019. PMID: 30262518 Free article.
Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Janik A, Schotte A, Hough D, Fleischhacker WW. Savitz AJ, et al. Among authors: ravenstijn p. Int J Neuropsychopharmacol. 2016 Jul 5;19(7):pyw018. doi: 10.1093/ijnp/pyw018. Print 2016 Jul. Int J Neuropsychopharmacol. 2016. PMID: 26902950 Free PMC article. Clinical Trial.
24 results